Searchable abstracts of presentations at key conferences in endocrinology

ea0025p49 | Clinical biochemistry | SFEBES2011

Hyponatraemia: the view from primary care

Tran Anh , Hyer Steve , Manghat Padmini , Lapsley Marta , Rodin Andrew

Introduction: Hyponatraemia is not uncommon in primary care and its management can be complex. It is vital that initial assessment is carried out properly as mismanagement can have serious consequences.Aim: To investigate general practitioners’ views and perceptions on the management of hyponatraemia encountered in primary care.Method: Local general practitioners were surveyed with a questionnaire via email and at local postgr...

ea0025p51 | Clinical biochemistry | SFEBES2011

A calcium sensing receptor mutation associated with hypercalcaemia and recurrent pancreatitis

Hall Lesley , Gaffney Dairena , Ramsay Joanne , Gallagher Andrew , Hinnie John

A 29-year-old man of South Asian descent presented with pancreatitis. Adjusted calcium was 3.10 mmol/l and PTH 9.8 μmol/l. Of note was that his parents were first cousins, and a cousin had undergone parathyroidectomy for hypercalcaemia.Pituitary, adrenal and thyroid function, calcitonin, prolactin, phosphate, magnesium, alkaline phosphatase and urinary catecholamines were all normal. 25-Hydroxyvitamin D was 20 nmol/l (15–100) The patient was th...

ea0025p205 | Growth and development | SFEBES2011

Identification of turner syndrome specific mRNA expression profiles that correlate with clinical response to growth hormone

Stevens Adam , Tajbakhsh Shahin , Whatmore Andrew , Westwood Melissa , Clayton Peter

Girls with Turner syndrome (TS) are treated with recombinant human growth hormone (rhGH) to improve their adult height but the gain is variable (0–20 cm). Current prediction models can account for only ~46% of the variability in the first year response to rhGH, thus genetic profiling has been suggested as a possible means of improving this prediction. The aim of this study was to explore mRNA expression profiles in an ex-vivo fibroblast model to characterise response to r...

ea0025p258 | Pituitary | SFEBES2011

An unusual presentation of thyrotroph adenoma

Raghavan Rajeev , Plaha Puneet , Nelson Richard , Lightman Stafford , Levy Andrew

Background and case: A 38-year-old man presented acutely with left-sided retro-orbital pain, a heavy/numb sensation in his left arm and blurred vision and diplopia on left lateral gaze. Baseline biochemistry, liver function and haematology were normal. His TSH was 3.9 (0.3–4 mU/l) and CRP 92 mg/l (<10). Plain CT head was unremarkable as was the MRI as reported, and atypical migraine was suspected. Vertical diplopia on left lateral gaze and left upper arm paraesthesia ...

ea0025p302 | Steroids | SFEBES2011

Cushing's syndrome in a patient with two lung tumours

Haniff Haliza , Scarsbrook Andrew F , Orme Stephen M

A 21-year-old man presented with 2 months history of weight gain, acne, hirsutism, lethargy, and muscle weakness. Examination revealed that he was cushingoid in appearance, had pustular acne and proximal myopathy. Initial 24 h urinary free cortisol was significantly raised at 5320 nmol/day (10–147), with raised ACTH of 120 ng/l (<47). He failed to suppress his cortisol on the low dose dexamethasone suppression test (baseline 708 nmol/l and 48 h 706 nmol/l). Urinary an...

ea0023oc1.2 | Oral Communications 1 | BSPED2009

Altered GH/IGF1 signalling in children born small for gestational age without catch up growth

Butcher Imogen , Whatmore Andrew , Murray Philip , Westwood Melissa , Clayton Peter

Background: Infants born small for gestational age (SGA) usually show catch-up growth during the first few years of post-natal life. However, some infants remain small and little is known about the factors governing their growth failure. GH and IGF1 receptor mutations only account for a minority of cases. We have now initiated an in vitro assessment of signalling molecules downstream of these receptors and evaluation of cell growth characteristics.<p class="abstext"...

ea0022p275 | Diabetes | ECE2010

Benefit of switching from rosiglitazone to pioglitazone on cardiovascular markers in routine clinical practice

Triay Jessica , Raghavan Rajeev , Day Andrew , Singhal Parag

Background and aims: Thiazolidinediones have been extensively used as second line agents in the management of type 2 diabetes. A small increased incidence of ischaemic heart disease was suggested by a meta-analysis of studies using Rosiglitazone. Similar meta-analysis of Pioglitazone did not show adverse cardiovascular outcomes. Our aim was to objectively evaluate the changes in glycaemic and lipid control in a controlled conversion from Rosiglitazone to Pioglitazone.<p cl...

ea0022p645 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long-term treatment of acromegaly with pasireotide (SOM230): results from a Phase II extension study

Farrall Andrew , Ruffin Matthieu , Wetli-Hermosillo Karina , Petersenn Stephan

Introduction: Pasireotide (SOM230) is a multi-receptor targeted somatostatin analogue with high binding affinity for sst1,2,3 and sst5. In a Phase II study of pasireotide in patients with active acromegaly, 27% achieved biochemical control after 1 month of octreotide s.c. followed by 3 months of pasireotide, and pituitary tumor volume decreased by >20% in 39% of patients. Results from the study’s extension phase are presented.<p class="abstex...

ea0021oc1.3 | Diabetes and metabolism | SFEBES2009

Adipose-specific knockout of androgen receptors in mice results in hyperinsulinaemia without obesity

McInnes Kerry , Smith Lee , Saunders Philippa , Andrew Ruth , Walker Brian

Background: Visceral fat is a key factor underlying type 2 diabetes. The amount and distribution of body fat is strongly influenced by sex steroids. Androgen receptors (ARs) are present in adipose tissue and are abundant in the detrimental visceral bed. Here, we sought to determine the contribution of the AR in adipose tissue to the pathophysiology of visceral obesity and type 2 diabetes.Methods: Male fat-specific AR-knockout (fARKO) mice (12 weeks; n...

ea0021p8 | Bone | SFEBES2009

Vitamin D deficiency in primary hyperparathyroidism: prevalence and complications

Jahagirdar Vidhya , Yahya Sundus , Bates Andrew , Rahim Asad

Primary hyperparathyroidism (1 in 1000) (1) and occult vitamin D deficiency (14% of the healthy adult population) are relatively common disorders (2). Hypercalciuria, renal tract calcification and reduced bone mineral density (BMD) are recognised complications of primary hyperparathyroidism. We report details of the prevalence of vitamin D deficiency and complications in patients with primary hyperparathyroidism.It is a retrospective study of 44 patients...